These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38928223)

  • 1. Methylation-Based Characterization of a New
    Burgermeister S; Stoykova S; Krebs FS; Zoete V; Mbefo M; Egervari K; Reinhard A; Bisig B; Hewer E
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
    Mito JK; Bishop JA; Sadow PM; Stelow EB; Faquin WC; Mills SE; Krane JF; French CA; Fletcher CDM; Hornick JL; Sholl LM; Jo VY
    Am J Surg Pathol; 2018 Aug; 42(8):1067-1075. PubMed ID: 29683816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.
    Dogan S; Frosina D; Fayad M; de Oliveira TB; Alemar B; Rosenblum M; Tang LH; Hameed M; Xu B; Ghossein RA; Chute DJ; Weigelt B; Jungbluth AA
    Mod Pathol; 2019 Feb; 32(2):205-215. PubMed ID: 30206411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation-based classification of sinonasal undifferentiated carcinoma.
    Dogan S; Vasudevaraja V; Xu B; Serrano J; Ptashkin RN; Jung HJ; Chiang S; Jungbluth AA; Cohen MA; Ganly I; Berger MF; Momeni Boroujeni A; Ghossein RA; Ladanyi M; Chute DJ; Snuderl M
    Mod Pathol; 2019 Oct; 32(10):1447-1459. PubMed ID: 31186531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas.
    Dogan S; Chute DJ; Xu B; Ptashkin RN; Chandramohan R; Casanova-Murphy J; Nafa K; Bishop JA; Chiosea SI; Stelow EB; Ganly I; Pfister DG; Katabi N; Ghossein RA; Berger MF
    J Pathol; 2017 Aug; 242(4):400-408. PubMed ID: 28493366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma.
    Jo VY; Chau NG; Hornick JL; Krane JF; Sholl LM
    Mod Pathol; 2017 May; 30(5):650-659. PubMed ID: 28084339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants.
    Dogan S; Frosina D; Geronimo JA; Hernandez E; Mohanty A; Bale T; Hechtman JF; Arcila ME; Hameed MR; Jungbluth AA
    Hum Pathol; 2020 Dec; 106():45-53. PubMed ID: 33017591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH2 -Mutated Sinonasal Tumors: A Review.
    Alzumaili B; Sadow PM
    Adv Anat Pathol; 2023 Mar; 30(2):104-111. PubMed ID: 36537260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1/2 Mutations in Sinonasal Undifferentiated Carcinomas : Previously Undescribed IDH2 R172K and R140x Variants.
    Kakkar A; Rathor A; Ashraf SF; Singh V; Sikka K; Jain D
    Am J Surg Pathol; 2022 Sep; 46(9):1284-1290. PubMed ID: 35486703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management.
    Riobello C; López-Hernández A; Cabal VN; García-Marín R; Suárez-Fernández L; Sánchez-Fernández P; Vivanco B; Blanco V; López F; Franchi A; Llorente JL; Hermsen MA
    Am J Surg Pathol; 2020 Mar; 44(3):396-405. PubMed ID: 31876581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies: Forty Molecularly Homogenous and Histologically Variable Cases With Favorable Outcome.
    Glöss S; Jurmeister P; Thieme A; Schmid S; Cai WY; Serrette RN; Perner S; Ribbat-Idel J; Pagenstecher A; Bläker H; Keber U; Stadelmann C; Zechel S; Johann PD; Hasselblatt M; Paulus W; Thomas C; Dohmen H; Baumhoer D; Frank S; Agaimy A; Schüller U; Vasudevaraja V; Snuderl M; Liu CZ; Pfister DG; Jungbluth AA; Ghossein RA; Xu B; Capper D; Dogan S
    Am J Surg Pathol; 2021 Sep; 45(9):1190-1204. PubMed ID: 34265800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
    Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
    Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
    Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
    J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2.
    Chen X; Yang P; Qiao Y; Ye F; Wang Z; Xu M; Han X; Song L; Wu Y; Ou WB
    Sci Rep; 2022 Nov; 12(1):18830. PubMed ID: 36335201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
    Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
    Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.